{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:27:38Z","timestamp":1793291258869,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11604-025-01886-3","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T03:00:35Z","timestamp":1760065235000},"page":"402-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Global research landscape of PSMA-targeted radiopharmaceuticals: a two-decade multidimensional bibliometric analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Ze-Lin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Qin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"1886_CR1","doi-asserted-by":"publisher","first-page":"1533532","DOI":"10.3389\/fimmu.2024.1533532","volume":"15","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Kadeerhan G, Zhang J, Guo W, Guo H, Wang D. Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology. Front Immunol. 2024;15:1533532.","journal-title":"Front Immunol"},{"issue":"3","key":"1886_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2967\/jnumed.121.262997","volume":"63","author":"AK Miyahira","year":"2022","unstructured":"Miyahira AK, Soule HR. The history of prostate-specific membrane antigen as a theranostic target in prostate cancer: the cornerstone role of the Prostate Cancer Foundation. J Nucl Med. 2022;63(3):331\u20138.","journal-title":"J Nucl Med"},{"key":"1886_CR3","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.2147\/IJN.S454128","volume":"19","author":"WG Lesniak","year":"2024","unstructured":"Lesniak WG, Boinapally S, Lofland G, Jiang Z, Foss CA, Behman Azad B, et al. Multimodal, PSMA-targeted, PAMAM dendrimer-drug conjugates for treatment of prostate cancer: preclinical evaluation. Int J Nanomedicine. 2024;19:4995\u20135010.","journal-title":"Int J Nanomedicine"},{"key":"1886_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-081522-031439","volume":"75","author":"LM Unterrainer","year":"2024","unstructured":"Unterrainer LM, Calais J, Bander NH. Prostate-specific membrane antigen: gateway to management of advanced prostate cancer. Annu Rev Med. 2024;75:49\u201366.","journal-title":"Annu Rev Med"},{"issue":"7","key":"1886_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00259-025-07102-8","volume":"52","author":"P Ritt","year":"2025","unstructured":"Ritt P, Fern\u00e1ndez R, Soza-Ried C, Nicolai H, Amaral H, Krieger K, et al. Biodistribution and dosimetry of [(177)Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(7):2431\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1886_CR6","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.7150\/thno.96738","volume":"14","author":"AT K\u00fcper","year":"2024","unstructured":"K\u00fcper AT, Kersting D, Telli T, Herrmann K, Rominger A, Afshar-Oromieh A, et al. PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: is there value beyond localization of disease? Theranostics. 2024;14(9):3623\u201333.","journal-title":"Theranostics"},{"issue":"1","key":"1886_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22(1):26\u201345.","journal-title":"Nat Rev Urol"},{"issue":"12","key":"1886_CR8","doi-asserted-by":"publisher","first-page":"e240080","DOI":"10.1148\/rg.240080","volume":"44","author":"LK Szidonya","year":"2024","unstructured":"Szidonya LK, Barwick TD, Challapalli A, Naik M, Eccles A, Barbon D, et al. PSMA radiotheranostics in prostate cancer: principles, practice, and future prospects. Radiographics. 2024;44(12):e240080.","journal-title":"Radiographics"},{"issue":"7","key":"1886_CR9","first-page":"995","volume":"66","author":"A Gafita","year":"2025","unstructured":"Gafita A, Schroeder JA, Ceci F, Oldan JD, Khandani AH, Lecouvet FE, et al. Treatment response evaluation in prostate cancer using PSMA PET\/CT. J Nucl Med. 2025;66(7):995\u20131004.","journal-title":"J Nucl Med"},{"issue":"19","key":"1886_CR10","doi-asserted-by":"publisher","first-page":"10897","DOI":"10.1021\/acs.jmedchem.9b01479","volume":"63","author":"J Cardinale","year":"2020","unstructured":"Cardinale J, Roscher M, Sch\u00e4fer M, Geerlings M, Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, et al. Development of PSMA-1007-related series of (18)F-labeled glu-ureido-type PSMA inhibitors. J Med Chem. 2020;63(19):10897\u2013907.","journal-title":"J Med Chem"},{"issue":"6","key":"1886_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2967\/jnumed.124.268818","volume":"66","author":"V Murthy","year":"2025","unstructured":"Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. The role of PSMA PET parameters as biomarkers for response to PSMA-targeted radiopharmaceutical therapy. J Nucl Med. 2025;66(6):833\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"1886_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41596-021-00662-7","volume":"17","author":"ME Rodnick","year":"2022","unstructured":"Rodnick ME, Sollert C, Stark D, Clark M, Katsifis A, Hockley BG, et al. Synthesis of (68)Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced (68)Ga as exemplified by [(68)Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nat Protoc. 2022;17(4):980\u20131003.","journal-title":"Nat Protoc"},{"issue":"41","key":"1886_CR13","doi-asserted-by":"publisher","first-page":"17097","DOI":"10.1021\/jacs.1c07377","volume":"143","author":"H Li","year":"2021","unstructured":"Li H, Luo D, Yuan C, Wang X, Wang J, Basilion JP, et al. Magnetic resonance imaging of PSMA-positive prostate cancer by a targeted and activatable Gd(III) MR contrast agent. J Am Chem Soc. 2021;143(41):17097\u2013108.","journal-title":"J Am Chem Soc"},{"issue":"3","key":"1886_CR14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.euo.2024.10.011","volume":"8","author":"CM Benitez","year":"2025","unstructured":"Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, et al. Treatment response assessment according to updated PROMISE criteria in patients with metastatic prostate cancer using an automated imaging platform for identification, measurement, and temporal tracking of disease. Eur Urol Oncol. 2025;8(3):700\u20138.","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"1886_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, H\u00fcsing J, Claassen K, M\u00f6ller L, Kaj\u00fcter H, Oesterling F, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024;25(9):1188\u2013201.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1886_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1053\/j.semnuclmed.2024.04.004","volume":"54","author":"A Al-Ibraheem","year":"2024","unstructured":"Al-Ibraheem A, Al-Abdallat H, Al-Rashdan R, Abdlkadir AS, Sweedat DA, Alyasjeen SF, et al. Navigating the Prostate Cancer frontier: a bibliometric and altmetric analysis of [(225)Ac]Ac-PSMA therapy. Semin Nucl Med. 2024;54(4):603\u201311.","journal-title":"Semin Nucl Med"},{"issue":"3","key":"1886_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1055\/a-2221-3036","volume":"63","author":"R Al-Rashdan","year":"2024","unstructured":"Al-Rashdan R, Al-Abdallat H, Sathekge MM, Mirzaei S, Shahait M, Al-Khawaldeh K, et al. Global research output of Lutetium-177 PSMA in prostate cancer: bibliometric and altmetric analyses. Nuklearmedizin. 2024;63(3):188\u201398.","journal-title":"Nuklearmedizin"},{"issue":"1","key":"1886_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s40001-023-01590-w","volume":"28","author":"H Zhang","year":"2023","unstructured":"Zhang H, Xiao L, Xie H, Li L. Hotspots and frontiers in PSMA research for prostate cancer: a bibliometric and visualization analysis over the past 20 years. Eur J Med Res. 2023;28(1):610.","journal-title":"Eur J Med Res"},{"key":"1886_CR19","doi-asserted-by":"publisher","first-page":"1397790","DOI":"10.3389\/fonc.2024.1397790","volume":"14","author":"M Sallam","year":"2024","unstructured":"Sallam M, Mohammadi M, Sainsbury F, Nguyen NT, Kimizuka N, Muyldermans S, et al. Bibliometric and scientometric analysis of PSMA-targeted radiotheranostics: knowledge mapping and global standing. Front Oncol. 2024;14:1397790.","journal-title":"Front Oncol"},{"issue":"5","key":"1886_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/jrsm.1729","volume":"15","author":"M Gusenbauer","year":"2024","unstructured":"Gusenbauer M. Beyond Google scholar, Scopus, and Web of Science: an evaluation of the backward and forward citation coverage of 59 databases\u2019 citation indices. Res Synth Methods. 2024;15(5):802\u201317.","journal-title":"Res Synth Methods"},{"issue":"2","key":"1886_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1096\/fj.07-9492LSF","volume":"22","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB j. 2008;22(2):338\u201342.","journal-title":"FASEB j"},{"issue":"1","key":"1886_CR22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/JS9.0000000000002095","volume":"111","author":"J Tian","year":"2025","unstructured":"Tian J, Dong YX, Wang L, Wu YM, Zhao ZY, Che GW. Mapping the evolution of 3D printing in cardio-thoracic diseases: a global bibliometric analysis. Int J Surg. 2025;111(1):1629\u201335.","journal-title":"Int J Surg"},{"issue":"1","key":"1886_CR23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12672-025-02181-3","volume":"16","author":"PY Che","year":"2025","unstructured":"Che PY, Zuo CJ, Tian J. Global trends in esophageal cancer and metabolic syndrome research: bibliometric analysis and visualization from 1995 to 2024. Discov Oncol. 2025;16(1):398.","journal-title":"Discov Oncol"},{"issue":"1","key":"1886_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12672-025-02018-z","volume":"16","author":"CJ Zuo","year":"2025","unstructured":"Zuo CJ, Tian J. Global trends and emerging research in nanotechnology for esophageal cancer: a comprehensive bibliometric analysis. Discov Oncol. 2025;16(1):262.","journal-title":"Discov Oncol"},{"issue":"1","key":"1886_CR25","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.autrev.2024.103697","volume":"24","author":"YX Dong","year":"2025","unstructured":"Dong YX, Zhou SC, Tian J. Advancing understanding of autoimmune disease-related interstitial lung disease (AD-ILD): a global perspective on research focus and future directions. Autoimmun Rev. 2025;24(1):103697.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1886_CR26","doi-asserted-by":"publisher","first-page":"103696","DOI":"10.1016\/j.autrev.2024.103696","volume":"24","author":"H Bai","year":"2025","unstructured":"Bai H, Tian J. Global research landscape on antiphospholipid syndrome and systemic lupus erythematosus: trends, collaborations, and future directions. Autoimmun Rev. 2025;24(1):103696.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1886_CR27","doi-asserted-by":"publisher","first-page":"103691","DOI":"10.1016\/j.autrev.2024.103691","volume":"24","author":"H Bai","year":"2025","unstructured":"Bai H, Tian J. Advancing the understanding of autoimmune\/inflammatory syndrome induced by adjuvants (ASIA): global research trends, key themes, and emerging frontiers. Autoimmun Rev. 2025;24(1):103691.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1886_CR28","doi-asserted-by":"publisher","first-page":"2488074","DOI":"10.1080\/21645515.2025.2488074","volume":"21","author":"CJ Zuo","year":"2025","unstructured":"Zuo CJ, Tian J. Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: global research trends, key themes, and emerging frontiers. Hum Vaccin Immunother. 2025;21(1):2488074.","journal-title":"Hum Vaccin Immunother"},{"issue":"10231","key":"1886_CR29","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"5","key":"1886_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid \u2076\u2078Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668\u201374.","journal-title":"J Nucl Med"},{"issue":"1","key":"1886_CR31","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1886_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.euo.2022.10.007","volume":"6","author":"KL Pomykala","year":"2023","unstructured":"Pomykala KL, Herrmann K, Lalumera E, Fanti S. Positive prostate-specific membrane antigen findings: how to interpret them. Eur Urol Oncol. 2023;6(2):113\u20135.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"1886_CR33","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.euo.2020.08.012","volume":"5","author":"AT Lenis","year":"2022","unstructured":"Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, et al. Prostate-specific membrane antigen positron emission tomography\/computed tomography compared with conventional imaging for initial staging of treatment-na\u00efve intermediate- and high-risk prostate cancer: a retrospective single-center study. Eur Urol Oncol. 2022;5(5):544\u201352.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"1886_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijrobp.2024.08.045","volume":"121","author":"C Udovicich","year":"2025","unstructured":"Udovicich C, Jia AY, Loblaw A, Eapen R, Hofman MS, Siva S. Evolving paradigms in prostate cancer: the integral role of prostate-specific membrane antigen positron emission tomography\/computed tomography in primary staging and therapeutic decision-making. Int J Radiat Oncol Biol Phys. 2025;121(2):307\u201316.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1886_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.euo.2024.11.002","volume":"8","author":"TFW Soeterik","year":"2025","unstructured":"Soeterik TFW, Heetman JG, Hermsen R, Wever L, Lavalaye J, Vinken M, et al. The added value of prostate-specific membrane antigen positron emission tomography\/computed tomography to magnetic resonance imaging for local staging of prostate cancer in patients undergoing radical prostatectomy. Eur Urol Oncol. 2025;8(3):731\u20138.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"1886_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/RLU.0000000000003496","volume":"46","author":"S Lennartz","year":"2021","unstructured":"Lennartz S, T\u00e4ger P, Zopfs D, Iuga AI, Reimer RP, Z\u00e4ske C, et al. Lymph node assessment in prostate cancer: evaluation of iodine quantification with spectral detector CT in correlation to PSMA PET\/CT. Clin Nucl Med. 2021;46(4):303\u20139.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"1886_CR37","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.euo.2024.01.002","volume":"7","author":"LM Wong","year":"2024","unstructured":"Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, et al. Fluorine-18-labelled prostate-specific membrane antigen positron emission tomography\/computed tomography or magnetic resonance imaging to diagnose and localise prostate cancer. A prospective single-arm paired comparison (PEDAL). Eur Urol Oncol. 2024;7(5):1015\u201323.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"1886_CR38","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"JP Buteau","year":"2024","unstructured":"Buteau JP, Moon D, Fahey MT, Roberts MJ, Thompson J, Murphy DG, et al. Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [(68)Ga]Ga-PSMA-11 positron emission tomography\/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. Eur Urol Oncol. 2024;7(3):544\u201352.","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"1886_CR39","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63(11):1644\u201350.","journal-title":"J Nucl Med"},{"issue":"8","key":"1886_CR40","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1097\/RLU.0000000000005986","volume":"50","author":"A Ghodsi","year":"2025","unstructured":"Ghodsi A, Demirci RA, Chen DL, Nelson PS, Schweizer MT, Yu EY, et al. The role of SPECT\/CT in 177 Lu-PSMA-617 theranostics: case-based review of response and progression patterns. Clin Nucl Med. 2025;50(8):e453\u201360.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1886_CR41","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.34749","volume":"154","author":"E Almuradova","year":"2024","unstructured":"Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, et al. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Int J Cancer. 2024;154(4):692\u2013700.","journal-title":"Int J Cancer"},{"issue":"12","key":"1886_CR42","first-page":"1939","volume":"65","author":"M Swiha","year":"2024","unstructured":"Swiha M, Pathmanandavel S, Papa N, Sabahi Z, Li S, Zheng A, et al. Comparison of posttherapy 4- and 24-hour [(177)Lu]Lu-PSMA SPECT\/CT and Pretherapy PSMA PET\/CT in assessment of disease in men with metastatic castration-resistant prostate cancer. J Nucl Med. 2024;65(12):1939\u201344.","journal-title":"J Nucl Med"},{"issue":"3","key":"1886_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam AO, et al. (177)Lu-PSMA SPECT quantitation at 6 weeks (Dose 2) predicts short progression-free survival for patients undergoing (177)Lu-PSMA-I&T therapy. J Nucl Med. 2023;64(3):410\u20135.","journal-title":"J Nucl Med"},{"key":"1886_CR44","doi-asserted-by":"crossref","unstructured":"Belabaci Z, Schmidt L, Sleiay M, Cou\u00f1ago F, Campos FL, Tolba M, Zilli T, Afshar-Oromieh A, Shelan M: Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2025.","DOI":"10.1007\/s00259-025-07627-y"},{"issue":"3","key":"1886_CR45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79(3):343\u201350.","journal-title":"Eur Urol"},{"issue":"4","key":"1886_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/RLU.0000000000004573","volume":"48","author":"RA Bundschuh","year":"2023","unstructured":"Bundschuh RA, Pfob CH, Wienand G, Dierks A, Kircher M, Lapa C. 177 Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177 Lu-PSMA-I&T. Clin Nucl Med. 2023;48(4):337\u20138.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1886_CR47","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-024-06959-5","volume":"52","author":"A G\u00e4ble","year":"2025","unstructured":"G\u00e4ble A, Dierks A, Rinscheid A, Patt M, Wienand G, Pfob CH, et al. Experience of rescue therapy with [(177)Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [(177)Lu]Lu-PSMA-I&T. Eur J Nucl Med Mol Imaging. 2025;52(3):970\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1886_CR48","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1007\/s00259-021-05354-8","volume":"48","author":"S Koschel","year":"2021","unstructured":"Koschel S, Taubman K, Sutherland T, Yap K, Chao M, Guerrieri M, et al. Patterns of disease detection using [(18)F]DCFPyL PET\/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial. Eur J Nucl Med Mol Imaging. 2021;48(11):3712\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1886_CR49","doi-asserted-by":"crossref","unstructured":"Perry E, Talwar A, Taubman K, Ng M, Wong LM, Booth R, Sutherland TR: [(18)F]DCFPyL PET\/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA <\u20090.5\u00a0ng\/mL. Eur J Nucl Med Mol Imaging 2021, 48(6):2038\u20132046.","DOI":"10.1007\/s00259-020-05143-9"},{"issue":"13","key":"1886_CR50","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1007\/s00259-023-06355-5","volume":"50","author":"Y Wang","year":"2023","unstructured":"Wang Y, Chen Z, Zhu Y, Zhao H, Li L, Huang G, et al. Total-body [(68) Ga]Ga-PSMA-11 PET\/CT improves detection rate compared with conventional [(68) Ga]Ga-PSMA-11 PET\/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(13):4096\u2013106.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1886_CR51","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00259-024-06980-8","volume":"52","author":"Q Chen","year":"2025","unstructured":"Chen Q, Dong L, Xu L, Zhao H, Li L, Huang G, et al. Comparison of clinical performance between late and standard total-body [(68) Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(4):1249\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1886_CR52","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00259-021-05497-8","volume":"49","author":"K Johnsson","year":"2022","unstructured":"Johnsson K, Brynolfsson J, Sahlstedt H, Nickols NG, Rettig M, Probst S, et al. Analytical performance of apromise: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging. 2022;49(3):1041\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1886_CR53","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2967\/jnumed.120.254623","volume":"62","author":"D Kostyszyn","year":"2021","unstructured":"Kostyszyn D, Fechter T, Bartl N, Grosu AL, Gratzke C, Sigle A, et al. Intraprostatic tumor segmentation on PSMA PET images in patients with primary prostate cancer with a convolutional neural network. J Nucl Med. 2021;62(6):823\u20138.","journal-title":"J Nucl Med"},{"issue":"11","key":"1886_CR54","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2967\/jnumed.124.267723","volume":"65","author":"A Gafita","year":"2024","unstructured":"Gafita A, Voter A, Shesadri S, Spitz A, Marshall CH, Rowe SP, et al. Initial experience with [(177)Lu]Lu-PSMA-617 after regulatory approval for metastatic castration-resistant prostate cancer: efficacy, safety, and outcome prediction. J Nucl Med. 2024;65(11):1724\u201330.","journal-title":"J Nucl Med"},{"key":"1886_CR55","doi-asserted-by":"publisher","first-page":"109339","DOI":"10.1016\/j.compbiomed.2024.109339","volume":"184","author":"FE \u00d6\u011f\u00fclm\u00fc\u015f","year":"2025","unstructured":"\u00d6\u011f\u00fclm\u00fc\u015f FE, Almal\u0131o\u011flu Y, Tamam M, Y\u0131ld\u0131r\u0131m B, Uysal E, Numano\u011flu \u00c7, et al. Integrating PET\/CT, radiomics and clinical data: an advanced multi-modal approach for lymph node metastasis prediction in prostate cancer. Comput Biol Med. 2025;184:109339.","journal-title":"Comput Biol Med"},{"issue":"5","key":"1886_CR56","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s00259-023-06555-z","volume":"51","author":"E Jafari","year":"2024","unstructured":"Jafari E, Zarei A, Dadgar H, Keshavarz A, Manafi-Farid R, Rostami H, et al. A convolutional neural network-based system for fully automatic segmentation of whole-body [(68)Ga]Ga-PSMA PET images in prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51(5):1476\u201387.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1886_CR57","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s11547-024-01820-z","volume":"129","author":"R Laudicella","year":"2024","unstructured":"Laudicella R, Comelli A, Schwyzer M, Stefano A, Konukoglu E, Messerli M, et al. PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI. Radiol Med. 2024;129(6):901\u201311.","journal-title":"Radiol Med"},{"key":"1886_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.05.014","author":"E Yazdani","year":"2025","unstructured":"Yazdani E, Sadeghi M, Karamzade-Ziarati N, Jabari P, Amini P, Vosoughi H, et al. Machine learning-based dose prediction in [(177)Lu]Lu-PSMA-617 therapy by integrating biomarkers and radiomic features from [(68)Ga]Ga-PSMA-11 positron emission tomography\/computed tomography. Int J Radiat Oncol Biol Phys. 2025. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.014.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1886_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/RLU.0000000000003585","volume":"46","author":"S Mostafapour","year":"2021","unstructured":"Mostafapour S, Gholamiankhah F, Dadgar H, Arabi H, Zaidi H. Feasibility of deep learning-guided attenuation and scatter correction of whole-body 68Ga-PSMA PET studies in the image domain. Clin Nucl Med. 2021;46(8):609\u201315.","journal-title":"Clin Nucl Med"},{"key":"1886_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004848","author":"R Sun","year":"2022","unstructured":"Sun R, Henry T, Laville A, Carr\u00e9 A, Hamaoui A, Bockel S, et al. Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy? J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004848.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1886_CR61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/cac2.12576","volume":"44","author":"Y Wu","year":"2024","unstructured":"Wu Y, Yi M, Niu M, Zhou B, Mei Q, Wu K. Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer Commun (Lond). 2024;44(7):739\u201360.","journal-title":"Cancer Commun (Lond)"},{"key":"1886_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010212","author":"J Chen","year":"2025","unstructured":"Chen J, Zhou Y, Pang Y, Fu K, Luo Q, Sun L, et al. FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)(2) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010212.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1886_CR63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, et al. Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol. 2023;84(5):491\u2013502.","journal-title":"Eur Urol"},{"issue":"6","key":"1886_CR64","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2967\/jnumed.123.267014","volume":"65","author":"M Swiha","year":"2024","unstructured":"Swiha M, Papa N, Sabahi Z, Ayati N, John N, Pathmanandavel S, et al. Development of a visually calculated SUV(mean) (HIT score) on screening PSMA PET\/CT to predict treatment response to (177)Lu-PSMA therapy: comparison with quantitative SUV(mean) and patient outcomes. J Nucl Med. 2024;65(6):904\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"1886_CR65","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00259-024-06949-7","volume":"52","author":"Y Li","year":"2025","unstructured":"Li Y, Li J, Yang J, Xiao L, Zhou M, Cai Y, et al. Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS \u2264 3 MRI. Eur J Nucl Med Mol Imaging. 2025;52(3):913\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01886-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01886-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01886-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:02:47Z","timestamp":1769846567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01886-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01886-3","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"No ethical approval was needed because this is not a human study, but only online information was used.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}